New patient trials surrounding the medication Retatrutide , specifically the 120mg formulation ZPHC ZPHC, reveal a significant effect on body mass loss and associated metabolic conditions . Researchers believe that this innovative compound, affecting both GLP-1 and GIP pathways , has the potenti